The integrin a9b1 binds a number of extracellular matrix components to mediate cell adhesion, migration and tissue invasion. Although expressed in a variety of normal human cells including endothelium, it is also expressed in cancer cells. We have previously shown that a9b1 binds VEGF-A to facilitate angiogenesis, an important component of the tumor microenvironment. As a9b1 induces accelerated cancer cell migration, we wished to determine what role it played in cancer growth and metastasis. In this study, we show that a9b1 expression induces molecular changes consistent with epithelial-mesenchymal transition. In addition, we found that a9b1 forms a tri-partite protein complex with b-catenin and E-cadherin, which dissociates following integrin activation and subsequent src and b-catenin phosphorylation. These findings were consistent in cells in which: a9b1 was exogenously over-expressed, or when its expression was suppressed in cancer cells endogenously expressing a9b1. These in vitro results are biologically significant as a9b1-expressing cancer cells induce greater tumor growth and metastases in mice as compared to the cells without a9b1 expression or when integrin expression is suppressed. Furthermore, integrin a9b1 is expressed in primary human small cell lung cancer and patients having a high expression of a9b1 demonstrated significantly worse long-term survival compared with patients with low a9b1 expression. These findings highlight a novel mechanism of integrin a9b1 function in human cancer.
INTRODUCTION
Epithelial-mesenchymal transition (EMT) represents a well co-ordinated series of molecular changes in epithelial cells including loss of E-cadherin expression, increased vimentin and N-cadherin 1 and rearrangement of cortical actin, imparting an increased migratory capacity to the resulting mesenchymal cells. 2 The timing and extent of EMT is essential for fetal development but is also associated with diseases such as fibrosis and cancer metastasis. 3, 4 In tumors, EMT imparts a more aggressive phenotype, ultimately resulting in metastasis by direct local tissue invasion or distantly through blood vessels and lymphatics. 5 The prototypic stimulus for EMT is TGF-b, which induces phosphorylation of b-catenin and subsequent activation of transcription factors including Snail. 6 TGF-b is not alone in its ability to induce EMT, various other growth factors and transmembrane receptors have been implicated, including the integrins. 1, 5, 7 Integrins are matrix adhesion receptors that can transduce bi-directional signals to regulate cancer cell migration and invasion facilitating mechanisms such as EMT, depending upon available ligand and their interactions with membrane receptors. 8 --12 Integrins a3b1, a5b1 and avb6 have all been shown to modulate TGF-binduced EMT through distinct mechanisms in a variety of tumor cell lines. 3,13 --15 EMT induces an increase in both avb6 and a5b1 expression to facilitate cell migration: avb6 through autocrine TGF-b activation, 13 and a5b1 through binding of autocrine fibronectin. 15 Integrin a3b1 facilitates cell--cell adhesion by formation of a complex with E-cadherin and b-catenin. 16 In kidney and lung epithelium, a3b1 complexes with E-cadherin and TGF-bR1 and its activation is required for b-catenin phosphorylation. 3, 14 Integrin a9b1 is expressed in human cancers and appears to correlate with higher grade tumors. 17 --19 Although we have recently shown that integrin a9b1 has a role in lymphangiogenesis, 20 --23 and angiogenesis 24, 25 the exact mechanisms by which it transduces a pro-cancerous effect is unclear. As integrins have been implicated in EMT 4 and having shown that a9b1 induces accelerated cancer cell migration through src, a signaling intermediate implicated in cancer metastasis, 26, 27 we postulated that a9b1 might promote carcinoma growth and metastasis via src-mediated EMT.
RESULTS
Exogenously expressed a9b1 promotes molecular and cytoskeletal changes consistent with EMT We have previously used SW480 colon carcinoma cells 7 transfected with integrin a9b1 25 and observed that, compared with mock, a9-transfected SW480 cells ( Figure 1a ) displayed a more spindle shape, suggestive of a mesenchymal phenotype. Immunoflourescent staining ( Figure 1a ) and immunoblots of cell lysates ( Figure 1b ) showed that compared with mock, SW480-a9 expressed less E-cadherin, more a-SMA and vimentin and demonstrated loss of cortical F-actin; all molecular changes consistent with EMT. These molecular changes increased significantly with a9b1 activation, and were associated with increased expression of the transcriptional repressor Snail (Figure 1c ), further supporting the notion that a9b1-induces EMT. In contrast, SW480-mock did not demonstrate these changes when activated by the common integrin ligand, plasma fibronectin (pFN). Transient a9-overexpression in other cancer cell lines also resulted in similar EMT changes measured by immunoblotting (Supplementary Figure S1A ) and immunocytochemistry (Supplementary Figure S1B ); helping to rule out the confounding effect of cell type.
a9b1 expressing cancer cells demonstrate increased migration and invasion in vitro
The functional consequences of EMT include increased cell migration, invasion and anchorage-independent growth; all of which were increased with expression of a9b1. Figure 1d shows that a9b1 expression increases both haptotaxis and chemotaxis of SW-480 cells; which were associated with an increased cellular expression of N-cadherin and loss of cortical actin, both markers of increased migratory capacity ( Figure 1c ). Furthermore, expression of a9b1 was associated with a time-dependent increase in invasion, increasing further when cells were treated with a9b1 ligand and significantly decreased by a9-specific inhibitors (Figure 1e ). Lending further support to the notion that a9b1 induces a transformed phenotype, SW480-a9 were found to have increased anchorage-independent growth (Supplementary Figure S1C ). Taken together, these results suggest that a9b1 can induce a more aggressive cancer cell phenotype by inducing EMT.
Activation of a9b1 results in src-dependent phosphorylation of b-catenin
Having recently shown src is essential for a9b1 signaling 28 and knowing src is implicated in EMT, 29 we investigated its role in a9b1-associated EMT. Figure 2a shows that association of src with integrin a9b1 is facilitated by a9b1 ligand and depends on the a9 subunit and not b1 ( Figure 2b ). During EMT there is loss of cell -cell contact resulting from b-catenin phosphorylation and disruption of the b-catenin/E-cadherin complex at the adherens junction. 13 Figure 2c shows that ligation of a9b1 induces phosphorylation of src-Y416 and also b-catenin-Y654, the tyrosine phosphorylation site associated with EMT. 14 Src also mediated a9b1-induced b-catenin phosphorylation and changes in E-cadherin and vimentin expression consistent with EMT (Supplementary Figure S2A ). In non-a9 expressing SW480 neither src nor b-catenin phosphorylation were significantly induced by pFN, suggesting other b1-integrins are not having a role (Figure 2c ).
a9b1 forms a complex with E-cadherin and b-catenin, which dissociates following a9b1 activation Similar to other integrins, 3, 14 we found that a9b1 co-localizes with both b-catenin and E-cadherin on the cell surface ( Figure 2d ). This co-localization is disrupted following a9b1 activation in SW480-a9 cells (Figure 2e ) and appears to be mediated by src (Supplementary Figure S2C ). Although the dissociation of this tripartite protein complex may be secondary to loss of E-cadherin function, when taken together our results appear to support a direct effect of a9b1-associated EMT. Furthermore, targeted knockdown of b-catenin in SW480-a9 cells decreased E-cadherin and increased vimentin expression and were associated with functional changes consistent with EMT: increased cell migration, invasiveness and decreased proliferation ( Figure 2f ). In contrast, expression of E-cadherin and vimentin did not change significantly when cells were exposed to src-targeted siRNA, and migration and invasion were significantly less ( Figure 2f , left panel).
b-catenin is also a component of the Wnt signaling pathway which is associated with EMT. 30, 31 Our data shows that wnt signaling does not appear to have a role in a9b1-associated EMT (Supplementary Figure S3 ). Blocking wnt signaling either by Dickkof1 (Dkk1), a Wnt signaling antagonist 32 or by siRNAmediated knockdown of lipoprotein receptor-related protein-6 (LRP6), the major wnt co-receptor, did not show any effect on a9b1-mediated pro-EMT changes in E-cadherin or vimentin (Supplementary Figure S3A 
a9b1-associated EMT is not modulated by other EMT-associated integrins or TGF-b
As integrins a3b1 and avb6 are known to regulate EMT through b-catenin phosphorylation, 13, 14 we next determined whether these integrins might influence a9b1-associated EMT. Using flow cytometry we found minimal expression of aVb6, no differential expression between SW480-mock and a9 cells (Supplementary Figure S4A ) and that expression was unaltered by culture conditions, type of matrix (Supplementary Figure S4A ) or cell culture time (data not shown). Integrins a3b1 and avb6 modulate EMT through their interactions with TGF-b, and modulating downstream SMAD2 signaling. 13, 14 However, we found no difference in SMAD2 phosphorylation in SW480-mock or SW480-a9 at baseline or following stimulation by ligand: pFN (common ligand to a3b1 and avb6) or a9-specifc ligand, TnfnRAA (Supplementary Figure S4B ). Furthermore, a9b1 expression in cancer cells did not alter TGF-b-induced EMT (Supplementary Figure S4C ) nor did TGF-b change cellular expression of a9b1 (Supplementary Figure 4D ). Taken together, these results suggest that unique to the integrins, a9b1 can induce EMT independent of TGF-b.
In cells expressing a9b1, total b-catenin is significantly decreased (Figure 2c ), suggesting that b-catenin is either trafficking to the nucleus or undergoing proteasomal degradation. Supporting this notion, we found proportionally greater accumulation of nuclear b-catenin in SW480-a9 compared with mock cells, suggesting that at least in part, there is increased transcriptional activity (Supplementary Figure S5A) . This is further supported by the increased proliferative capacity of SW480-a9, which can be blocked by inhibiting a9b1 (Supplementary Figure  S5B ,C). a9b1 promotes tumor growth, vasculogenesis and metastasis We next performed tumor experiments to determine the pro-carcinogenic effects of a9b1 in vivo. Tumors formed in mice from flank injection of SW480-a9 cells were up to three times larger than tumors formed from SW480-mock cells (Figure 3a ), and were associated with increased intra-tumoral angiogenesis and lymphangiogenesis ( Figure 3b ) and displayed altered cadherin and vimentin expression consistent with EMT ( Figure 3c ).
Also consistent with an EMT phenotype, animals injected with SW480-a9 cells demonstrated significantly greater metastasis with marked inguinal lymphadenopathy and widespread lung and liver metastases (Figure 3d ). In contrast, only infrequent metastases could be detected in mice injected with SW480-mock cells (data not shown).
Endogenous a9b1 mediates EMT in lung carcinoma cells and increases cell migration and invasiveness
Having shown that EMT and metastatic cell behavior can be induced by the exogenous over-expression of a9b1, we next determined whether endogenously expressed integrin in lung cancer cells had a comparable action. Using flow cytometry ( Figure 4a ) and immunoblotting ( Figure 4b ), we found that a9b1 expression was variable but appeared more robust in human small cell lung cancer (SCLC) compared with NSCLC. In addition, LLC1, a mouse model cell line for lung carcinoma, also expressed integrin a9b1. Compared with normal bronchial epithelium (NHBE), these cancer cell lines showed evidence of EMT, as measured by E and N-cadherin expression. However, those cells expressing a9b1 demonstrated relatively less expression of E-cadherin and higher expression of N-cadherin and the extent of colony formation by these cancer cells on soft agar was dependent on the extent of a9b1 expression ( Supplementary Figure S6A,B) . Integrin a9b1 appears to induce a functionally relevant EMT phenotype in these lung cancer cells as demonstrated by increased a9b1-dependent adhesion (Figure 4c ), migration ( Figure 4d ) and Matrigel invasion (Figure 4e ). Although the overall extent of the response varied, they were mostly proportional to the magnitude of a9b1 expression.
a9b1-associated EMT was dependent on the expression level of the integrin. The change in expression of E-cadherin and vimentin following a9b1 activation was comparable to that induced by TGF-b in high a9b1-expressing LLC-1, intermediate in the minimally expressing A549, whereas NHBE or H69 cells showed no significant change in expression of E-cadherin and vimentin (Figure 4f ). Taken together, these findings support a physiologically relevant role for endogenous a9b1 in the induction of EMT in human cancer cells in vitro.
Suppression of a9 expression decreases tumor growth and metastasis
Having shown that endogenously expressed a9b1 confers an EMT phenotype and more aggressive cancer attributes, we next assessed EMT when a9 expression was suppressed using a9-targeted lentiviral shRNA (Figure 5a ). As expected, a9 depleted LLC-1 demonstrated significantly decreased adhesion on TnfnRAA (Figure 5b) whereas cell adhesion to pFN, a non-a9b1 ligand, was not affected. Similarly, migration and invasion (Figures 5c and d) were significantly decreased in cells expressing a9-targeted shRNA suggesting an inhibitory effect on EMT.
This inhibition of adhesion, migration and invasion was accompanied by changes in EMT markers. Compared with control LLC-1, a9-depleted cells grown on a9b1-specific ligand, demonstrated neither a decrease in E-cadherin nor an increase in vimentin, aSMA or Snail, suggesting that the process of a9b1induced EMT was blocked (Figure 5e ). Furthermore, the a9b1specific ligand, TnfnRAA, did not significantly activate the pro-EMT signaling intermediates, Src or b-catenin. Taken together, these findings provide further support for a9b1 inducing physiologically relevant EMT through src signaling.
The relevance of a9b1-associated EMT in vitro was confirmed by in vivo tumor studies using shRNA to deplete LLC1 cells of a9. Figure 5f demonstrates that tumors formed by a9-depleted cells (shRNA-a9), were at least half the size of those formed from cells with endogenous expression of a9b1 (shRNA-Cont). Furthermore, cancer cell metastasis was negligible in mice injected with a9-depleted LLC-1 compared with those injected with cells expressing a9b1 (Figure 5g ).
High expression of integrin a9b1 in human SCLC is a prognostic indicator of poor survival On the basis of our in vitro and in vivo data, we postulated that the extent of a9b1 expression in SCLC might correlate with the severity of disease. We analyzed SCLC tissue from 15 patients and found variable a9b1 expression both by immunoblot ( Figure 6a ) and RT-PCR (data not shown). Tumors from three separate patients were also used for immunohistochemistry which confirmed the expression of a9b1 on the surface of SCLC cells (Figure 6b ). Subsequently, we were able to separate patients on the basis of the extent of a9b1 expression in their tumor tissue: 11 high expressers and 4 low expressers. Figure 6c tables the characteristics of the patients in relation to the degree of a9b1 activity and is highlighted by significant differences in stage of disease and survival time. The average survival for patients with high a9b1 was 19 mo compared with 30 mo in patients with low a9b1 expression (Po0.001), (Figure 6d ).
DISCUSSION
The cellular mechanisms that induce EMT are complex 3, 5, 26 and the role of integrins has been well established under the paradigm of TGF-b-induced EMT. 33 In contrast, our findings show that in cancer cells, a9b1 expressed exogenously or endogenously can trigger EMT, in a TGF-b-independent fashion and that expression of a9b1 and its pro-EMT effects are not modulated by TGF-b. These results suggest there is at least one distinct integrin pathway regulating EMT, which is not surprising as tumor stroma provides a rich supply of integrin ligands. 34 Although we did not examine expression of all integrins, our findings also suggest that a9b1 does not require or promote the increased expression of other known pro-EMT integrins such as avb6 or a3b1. Other transmembrane receptors are known to partner with integrins to induce EMT without a growth factor stimulus 7 such as the serine protease TMPRSS4, which requires the synergistic action of active integrin a5b1. 35 Whether a9b1 functions in concert with other transmembrane proteins to facilitate EMT is yet to be determined.
Integrin a9b1 also distinguishes itself from other integrins such as a5b1 and a3b1 as its pro-EMT effect is transduced without a requirement for a change in expression. Following ras transformation of mammary epithelial cells, the resulting increased expression of a5b1 does not initiate EMT, 15 and expression of a3b1 alone is not sufficient to induce EMT as suggested by a3-null alveolar cells, which express similar amounts of E-cadherin to a3expressing cells. 14 Although TGF-b does induce increased expression of avb6, it is unknown whether the exogenous expression of avb6 might itself induce EMT. However, this would seem unlikely since the function of increased avb6 is to activate autocrinederived TGF-b. 13 Whether integrin a9b1 induces autocrine TGF-b production and presumably activation of TGF-b receptor is yet to be determined but seems unlikely as we found no significant SMAD2 activation under our experimental conditions. Our findings implicate src as a signaling intermediate for a9b1associated EMT acting by facilitating disassociation of E-cadherin and b-catenin, which is consistent with previous reports showing src-induced effects on the cytoskeleton and E-cadherin/ b-catenin. 29 The relevance of these molecular effects was confirmed by the inhibition of cancer cell migration and invasion, both functional EMT effects. In human carcinomas the role of src is well established with more than half of lung carcinomas demonstrating aberrantly activated src. 36 Further, cancer research should focus on determining whether co-expression of a9b1 directly contributes to the deregulation of src activity or if a9b1 can induce EMT in cells lacking activated src.
The importance of a9b1 in human cancer is supported by reports of its expression in breast, brain and lung cancer. 18, 37, 38 We show for the first time a clinical relevance for high expression of a9b1 in SCLC namely a decreased patient survival by 11 months. These findings are tempered by the low number of patients included in our study, which reflects clinical practice in which few patients undergo surgical procedures for diagnosis or treatment. This not withstanding; our results suggest that future research should focus on confirming these findings. Taken together, with our previous work it appears a9b1 may promote the cancer process through multiple mechanisms including effects on cell migration and invasion, induction of nitric oxide production, 28 angiogenesis 24 and lymphangiogenesis 20, 22 and now promotion of EMT. Our findings present cancer researchers with novel approaches to not only deciphering the carcinogenic trigger but also to better understand the interplay between the seemingly separate EMT mechanisms of TGF-b and integrin a9b1. Furthermore, our findings highlight the need for developing novel therapies targeting more than one pathogenic pathway and identify integrin a9b1 as a strong candidate for pharmacotherapy in human cancer.
MATERIALS AND METHODS Materials
Mouse monoclonal antibodies to a9b1: Y9A2, NC4, polyclonal anti a9-serum and TNfnRAA (gift from Dr Dean Sheppard University of California San Francisco, CA, USA (UCSF)); mAb against murine a9b1 (R&D, Minneapolis, MN, USA), b-Actin and GAPDH (Sigma, St Louis, MO, USA), E-cadherin, N-cadherin and b-catenin (BD Biosciences, Frankin Lakes, NJ, USA), b-catenin-Y654 (Invitrogen, Carlsbad, CA, USA). Rabbit polyclonal antibodies: Src-Y416, SMAD2-ser245/250/255, Src, vimentin, Snail, HDAC1, Erk2 and LRP6 (Cell Signaling Technologies, Danvers, MA, USA), anti a3b1, avb6, anti-SMAD2 (Millipore-Upstate, Lake Placid, NJ, USA); anti-aSMA (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-CD31 (Dako, Glostrup, Denmark), antipodoplanin (D2-40, Covance, Princeton, NJ, USA). Phycoerythrin-conjugated goat anti-mouse (Jackson Immunoresearch, West Grove, PA, USA); Horseradish peroxidase-conjugated anti-mouse and anti-rabbit antibodies (Amersham Biosciences, Piscataway, NJ, USA). pFN (Chemicon, Temecula, CA, USA), wnt3A and Dkk1 (R&D, Minneapolis, MN, USA); TGFb (Dr E Leof, Mayo Clinic, Rochester, MN, USA), src inhibitor, PP1 (BioMol International, Plymouth Meeting, PA, USA), VLO5 (Dr Cezary Marcinkiewicz, Temple University, Philadelphia, PA, USA).
Cell culture SW480-a9 or mock cells were cultured as previously described. 24, 28 A549 and Lewis lung carcinoma cells (LLC-1) cultured in F12K/DMEM medium with10% FBS. All other human lung carcinoma cell lines (ATCC) cultured in RPMI with 10% FBS. Primary NHBE cells: specialized medium (Lonza, Walkersville, MD, USA).
siRNA, plasmids and cell transfection
Integrin a9-EGFP-N3 expression vector (Addgene, Cambridge, MA, USA), siRNA oligonucleotides, negative control (Ambion, Austin, TX, USA) and siRNA to human b-Catenin, c-Src (Santa Cruz Biotechnology) and LRP6 (Cell Signaling) performed as described previously. 28 Lentivirus packaging; ViraPower Lentiviral Expression System (Invitrogen, Life Technologies). Using Lipofectamine-2000, 293FT cells were co-transfected with ViraPower DNA mix and plasmid (pLKO.1-puro) encoding shRNA-targeting murine a9subunit (Mayo Clinic RNA Resource) and supernatants collected 48 --72 h after transfection. LLC-1 cells were transduced in the presence of 6 mg/ml polybrene (Sigma-Aldrich), and stable clones selected in 10 mg/ml puromycin.
Immunoprecipitation, SDS --PAGE and immunoblot analysis
Serum-starved cells were trypsinized, washed with PBS and suspended in DMEM. In a 6-well plate, 1 Â 10 6 cells were added to wells coated or not with 10 mg/ml TnfnRAA or pFN, incubated for various times and lysed in RIPA buffer as previously described. 28 Protein lysates from fresh frozen tissue B50 mg were obtained by pulverizing in RIPA buffer. After 20 min incubation on ice, lysates were cleared by centrifugation and immunoprecipitation and immunoblotting performed as previously described. 28 To detect nuclear translocation of b-catenin, nuclear and cytoplasmic proteins were extracted using 'NE-PER Extraction Reagents (Thermo Scientific, Rockford, IL, USA) and immunoblotted for b-catenin. Extraction purity was determined by immunoblotting for Erk2 and HDAC1. 
Fluorescence microscopy
Cells cultured on sterile glass cover slips were rinsed with PBS, fixed, and incubated with antibody in 5% normal goat serum (Millipore-Upstate) at 4 1C overnight. Cells were washed, incubated with anti mouse IgG conjugated with Alexa Fluor-594 (or -488) (BD Biosciences) for 1 h. The cytoskeleton of fixed cells was immunostained with Texas-Red phalloidin and coverslips mounted with Slowfade containing DAPI (Invitrogen). Images were acquired as previously described. 28 Co-localization of integrin a9b1 with b-catenin (or E-cadherin) was determined using appropriate primary antibodies followed by incubation with Alexa-Fluor-labeled secondary antibodies. Immunostained cells were analyzed by confocal microscopy (Zeiss/SM510, Thorwood, NY, USA); Â 100 oil DIC objective with B0.5 mm optical sectioning.
Flow cytometry
Single-cell suspensions were rinsed and suspended in PBS at a density of 0.5 --1 Â 10 6 per ml, incubated with appropriate primary antibody for 30 min. Subsequent staining with phycoerythrin-conjugated secondary antibody, acquisition and data analysis was performed as previously described. 28 Cell adhesion assays Cell adhesion assays were performed as previously described 28 in flat bottom 96-well microtiter plates (ICN, Linbro/Titertek) coated with 10 mg/ml TnfnRAA or FN at 37 1C for 1 h, blocked with 1%BSA (Sigma) for 30 min. 5 Â 10 4 cells suspended in basal medium were plated in each well and when indicated incubated with a9b1 inhibitors; Y9A2 (20 mg/ml) or 50 mM VLO5 for 30 min.
Cell migration and invasion assays
Cell migration assays were performed as previously described. 24, 28 Haptotaxis: 10 mg/ml of TnfnRAA or FN for 1 h at 37 1C; chemotaxis: medium with 10% FBS. 5 Â 10 4 cells were added to the top chamber, with 30 min inhibitor incubation. Migration time of 12 --16 h at 37 1C. Invasion assays were performed using BD BioCoat (8 mm pore size) Matrigel chambers (Becton Dickinson, San Jose, CA, USA) as per the manufacturer's instructions. Briefly, cells treated with or without inhibitors were placed in the top chamber and 10% FBS for chemoattractant in bottom chamber. After 14 --16-hrs (A549 and LLC-1) or 24 --36 h (SW480, SCLC lines), invaded cells were fixed, stained (Hema-3 kit, Fisher Scientific, Kalamazoo, MI, USA) and counted in four separate view fields by light microscopy (Axiostar, Zeiss).
Cell proliferation assay 2 Â 10 3 SW480-mock or SW480-a9 cells in full growth medium were added to 12-well plates (Costar, Cambridge, MA, USA), trypsinized and counted using a hemocytometer. For BrdU assays cells were grown overnight in 96well plates, in the absence or presence of 50 mM VLO5 for 16 h. Medium containing BrdU was added for 2 h and uptake measured with ELISA (RPN 250, Amarsham Biosciences) as per the manufacturer's instructions.
Soft agar assay
To prevent cell settling, bottom plugs (0.5 ml, 0.8% Sea Plaque-agarose, 10% FBS/DMEM; FMC Bioproducts, Philadelphia, PA, USA) were casted in 12-well plates (Costar). Top plugs (1 ml, 0.4% agarose, 10% FBS/DMEM), and 10 3 cells with or without 50 mM VLO5 were incubated for14 days at 37 1C. The number of colonies 450 mm diameter were scored using Gelcount (Oxford Optronix, Oxford, UK).
Animal tumor studies
All experiments were IACUC approved and animals cared for in accordance with IACUC guidelines. 1 Â 10 6 SW480-mock or a9 cells were injected subcutaneously in the flank of Nude mice (n ¼ 5). After 35 days, tumor volume was measured (lxwxh/2). To study metastasis, cells were injected through the tail vein and on day 45 tissues harvested for histology. In other experiments, 0.5 Â 10 6 LLC-1 cells were transduced with lentivirus carrying control or a9-specific shRNA and were injected subcutaneously in the flank (n ¼ 5) or tail vein (n ¼ 3) of nude mice.
Human lung cancer tissues
The Mayo Clinic IRB approved all human studies. Fresh frozen lung cancer specimens were from the Mayo Clinic Lung Cancer Specimen Registry. Overall, 15 SCLC samples were analyzed for expression of a9b1 and patient clinical characteristics. Histology was verified by a Board Certified lung pathologist (MCA). The patient clinical data was analyzed in a blinded fashion (BPW). Survival (months) was from diagnosis to death.
Histology and immunohistochemistry
Mouse tissue was fixed in 10% formalin, embedded in paraffin and 5 mm sections stained with H&E or immunostained for PECAM1 (CD31) or podoplanin (D2-40). 5 Human SCLC samples and matched normal lung were immunostained with a9b1-specific rabbit antibody (1:250) overnight at 4 1C followed by biotinylated goat anti-rabbit secondary antibody (1:200), streptavidin-peroxidase (1:100), then 3,3 0 -diaminobenzidine (Amresco, Solon, OH, USA) and peroxide. Slides were rinsed, counterstained with hematoxylin, dehydrated and mounted. Images were obtained by scanning laser microscopy (Axiostar, Zeiss) or with NanoZoomer Digital Pathology software (Hamamatsu Photonics, Bridgewater, NJ, USA).
Statistical methods
Unless otherwise indicated, data presented as mean±s.e. from three or more experiments; P values determined using paired student's t-tests. Immunoblots were performed at least three times and representative examples presented. Statistical analysis of patient survival and clinical characteristics was performed using multivariate analysis with a P-value o0.05.
